MRI T2 lesion burden in multiple sclerosis

Background: Previous studies have shown only modest correlation between multiple sclerosis (MS) lesions on MRI and clinical disability. Objective: To investigate the relationship between proton density/T2-weighted (T2) burden of disease (BOD) quantitatively measured on MRI scans and clinical determinants including disability. Methods: Using the Sylvia Lawry Centre for Multiple Sclerosis Research (SLCMSR) database, the authors studied baseline T2 BOD data from a pooled subsample of 1,312 placebo MS patients from 11 randomized controlled trials. Univariate comparisons guided development of multiple regression models incorporating the most important clinical predictors. Results: Significant, although weak to moderate, correlations were found between T2 BOD and age at disease onset, disease duration, disease course, disability (as measured by the Expanded Disability Status Scale [EDSS]), relapse rate, certain presenting symptoms, and gadolinium enhancement. An unexpected but key finding that persisted in the multiple regression analyses was a plateauing relationship between T2 BOD and disability for EDSS values above 4.5. Conclusions: This study confirmed the limited correlation between clinical manifestations and T2 burden of disease (BOD) but revealed an important plateauing relationship between T2 BOD and disability.

[1]  J. Wolinsky,et al.  Linomide in relapsing and secondary progressive MS , 2000, Neurology.

[2]  A J Thompson,et al.  Correlations between changes in disability and T2‐weighted brain MRI activity in multiple sclerosis , 1995, Neurology.

[3]  Correlation between magnetic resonance imaging and clinical parameters in multiple sclerosis , 1995, Acta neurologica Scandinavica.

[4]  Marco Rovaris,et al.  Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis. , 2003, AJNR. American journal of neuroradiology.

[5]  B. Trapp,et al.  Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease , 2003, Journal of the Neurological Sciences.

[6]  G. Zhao,et al.  Effect of interferon β-1b in MS , 2000, Neurology.

[7]  T. Gasser,et al.  Body Composition Abnormalities in Children with Prader-Willi Syndrome and Long-Term Effects of Growth Hormone Therapy , 2000, Hormone Research in Paediatrics.

[8]  M Filippi,et al.  Correlation between brain MRI lesion volume and disability in patients with multiple sclerosis , 1996, Acta neurologica Scandinavica.

[9]  Hompson,et al.  A LONGITUDINAL STUDY OF ABNORMALITIES ON MRI AND DISABILITY FROM MULTIPLE SCLEROSIS , 2002 .

[10]  C. Svarer,et al.  Correlations of brain MRI parameters to disability in multiple sclerosis , 2001, Acta neurologica Scandinavica.

[11]  Frederik Barkhof,et al.  Patterns of Brain Magnetic Resonance Abnormalities on T2-Weighted Spin Echo Images in Clinical Subgroups of Multiple Sclerosis: A Large Cross-Sectional Study , 1998, European Neurology.

[12]  D. Paty,et al.  Magnetic resonance imaging results of the PRISMS trial: A randomized, double‐blind, placebo‐controlled study of interferon‐β1a in relapsing‐remitting multiple sclerosis , 1999 .

[13]  D. Ruppert.  The Elements of Statistical Learning: Data Mining, Inference, and Prediction , 2004 .

[14]  J K Udupa,et al.  Relapsing-remitting multiple sclerosis: longitudinal analysis of MR images--lack of correlation between changes in T2 lesion volume and clinical findings. , 1999, Radiology.

[15]  A. J. Thompson,et al.  Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis , 2003, Journal of Neurology.

[16]  Alan C. Evans,et al.  Improved correlation between scores on the expanded disability status scale and cerebral lesion load in relapsing-remitting multiple sclerosis. Results of the application of new imaging methods. , 1998, Brain : a journal of neurology.

[17]  Andrew Riddehough,et al.  Clinical and Magnetic Resonance Imaging Changes Correlate in a Clinical Trial Monitoring Cyclosporine Therapy for Multiple Sclerosis , 1997, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[18]  R. Kikinis,et al.  Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage , 2000, Journal of Neuroimmunology.

[19]  S. le Cessie,et al.  Predictive value of statistical models. , 1990, Statistics in medicine.

[20]  A. Thompson,et al.  The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. , 1998, Brain : a journal of neurology.

[21]  C. Pozzilli,et al.  MRI measures and their relations with clinical disability in relapsing-remitting and secondary progressive multiple sclerosis , 1997, Multiple sclerosis.

[22]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[23]  C Confavreux,et al.  Relapses and progression of disability in multiple sclerosis. , 2000, The New England journal of medicine.

[24]  F. Barkhof,et al.  Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. , 1998, Brain : a journal of neurology.

[25]  A. Thompson,et al.  Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. , 1990, BMJ.

[26]  Massimo Filippi,et al.  MRI techniques to monitor MS evolution: The present and the future , 2002, Neurology.

[27]  Richard F. Gunst,et al.  Applied Regression Analysis , 1999, Technometrics.